Dr. Immanuel Lerner, C.E.O.
Dr. Lerner has extensive experience in
neurobiology, immunology and cancer research
using in-vitro and in-vivo models. Immanuel was
the key in delivering Pepticom's initial in-vitro
proofs of concepts, blocking Toll-like receptor
activation in primary mouse macrophages. He
holds M.Sc. in biochemistry with distinction and
earned a Ph.D. from the Hebrew University of
Jerusalem, followed by postdoctoral research in
the field of circadian biology.
Dr. Amit Michaeli, C.R.O.
Pepticom's algorithms were developed during
Amit's thesis in the Hebrew University of
Jerusalem. Amit has extensive algorithm
development experience, in both the chemical
and financial fields. Amit currently focuses his
efforts in Pepticom on the development of new
models that define conformational entropy and
models of small molecules based on peptide
Dr. Maayan Elias Robicsek, B.D.O.
Dr. Maayan studied has a BSc. Pharm degree from the
Hebrew university and has 12 years of experience in the field.
She earned her PhD from the Hebrew university in the
medicinal chemistry creating unique databases and prediction
models for Cytochrome P450 inhibitors and substrates.
Additionally, Maayan holds a master in Business Administration (MBA)
specializes in Finance, general and strategic management.
Professor Amiram Goldblum, Director and Founder
Following his earlier studies of Chemistry and Physics and research Quantum Chemistry, Prof. Goldblum is Head
of the Molecular Modeling and Drug Design and Discovery Unit at the Institute for Drug
Research of the Hebrew University. Prof. Goldblum is a world renowned scientist
with more than 100 publications in scientific journals and is a requested speaker in scientific conferences.
Professor Anwar Rayan, Founder
Dr. Anwar Rayan is a research associate at the Hebrew university of Jerusalem and a
researcher at the QRC - Qasemi Research Center, Alkasemi College. Dr. Rayan has
gained vast experience in the field of drug discovery and algorithms' development while working at the School of Pharmacy at
the Hebrew University in Jerusalem and at FMP in Berlin. Dr. Rayan is expert in the field
of bioinformatics, chemoinformatics, drug design and drug discovery. He contributed
to the development of novel tools for protein/peptide structure prediction, protein-protein
docking, drug-likeness, molecular bioactivity indexing. He holds B.Sc. in chemistry with
distinction and earned a Ph.D. degree in medicinal chemistry from the Hebrew University of Jerusalem.
Board of Directors
Prof. Amiram Goldblum
Dr. Shmulik Ittah
Dr. Immanuel Lerner
Dr. Amit michaeli